Zealand Pharma A/S (OTCMKTS:ZLDPF) Issues Quarterly Earnings Results, Beats Expectations By $8.47 EPS

Zealand Pharma A/S (OTCMKTS:ZLDPF) released its earnings results on Thursday. The company reported $8.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $8.47, Zacks reports. The company had revenue of $698.62 million for the quarter, compared to analyst estimates of $692.12 million. Zealand Pharma A/S had a net margin of 58.86% and a return on equity of 18.53%.

Zealand Pharma A/S Stock Performance

Shares of Zealand Pharma A/S stock remained flat at $52.68 during trading on Friday. 11 shares of the stock were exchanged, compared to its average volume of 329. The stock has a fifty day moving average price of $45.69 and a 200-day moving average price of $49.49. Zealand Pharma A/S has a fifty-two week low of $35.93 and a fifty-two week high of $83.12. The company has a market capitalization of $3.77 billion, a price-to-earnings ratio of 8.74 and a beta of 0.88. The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17.

Analyst Ratings Changes

Several research firms have commented on ZLDPF. Berenberg Bank downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Zacks Research lowered Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a report on Thursday. Jefferies Financial Group cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Finally, Wolfe Research cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold”.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.